What do systematic reviews say?

First‐line thiazides vs beta‐blocker

• First‐line diuretics versus other classes of antihypertensive drugs for hypertension 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 6569 participants
  Low

First‐line thiazides vs beta‐blocker

• First‐line diuretics versus other classes of antihypertensive drugs for hypertension 2023 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 18501 participants
  Moderate

RAS inhibitors vs beta‐blocker

RAS inhibitors showed no clear difference in all‐cause death compared with beta‐blockers (low certainty).

• First‐line drugs inhibiting the renin angiotensin system versus other first‐line antihypertensive drug classes for… 2018 · Cochrane Headline outcomes only
  RR 0.89 [0.78, 1.01]
  1 study · 9193 participants
  Low

RAS inhibitors vs beta‐blocker

RAS inhibitors may leads to lower total cardiovascular events compared with beta‐blockers (low certainty).

• First‐line drugs inhibiting the renin angiotensin system versus other first‐line antihypertensive drug classes for… 2018 · Cochrane Headline outcomes only
  RR 0.88 [0.8, 0.98]
  2 studies · 9239 participants
  Low

RAS inhibitors vs beta‐blocker

RAS inhibitors showed no clear difference in total heart failure compared with beta‐blockers (low certainty).

• First‐line drugs inhibiting the renin angiotensin system versus other first‐line antihypertensive drug classes for… 2018 · Cochrane Headline outcomes only
  RR 0.95 [0.76, 1.18]
  1 study · 9193 participants
  Low

RAS inhibitors vs beta‐blocker

RAS inhibitors showed no clear difference in total myocardial infarction compared with beta‐blockers (low certainty).

• First‐line drugs inhibiting the renin angiotensin system versus other first‐line antihypertensive drug classes for… 2018 · Cochrane Headline outcomes only
  RR 1.05 [0.86, 1.27]
  2 studies · 9239 participants
  Low

RAS inhibitors vs beta‐blocker

RAS inhibitors may leads to lower total stroke compared with beta‐blockers (low certainty).

• First‐line drugs inhibiting the renin angiotensin system versus other first‐line antihypertensive drug classes for… 2018 · Cochrane Headline outcomes only
  RR 0.75 [0.63, 0.88]
  1 study · 9193 participants
  Low

Intervention not reported

The intervention probably leads to lower all‐cause mortality at maximum (moderate certainty).

• Beta‐blockers in patients without heart failure after myocardial infarction 2021 · Cochrane Headline outcomes only
  RR 0.81 [0.73, 0.9]
  21 studies · 22085 participants
  Moderate

Intervention not reported

The intervention may leads to lower major cardiovascular events (cardiovascular mortality or non‐fatal… (low certainty).

• Beta‐blockers in patients without heart failure after myocardial infarction 2021 · Cochrane Headline outcomes only
  RR 0.72 [0.62, 0.83]
  15 studies · 14994 participants
  Low

Intervention not reported

The review found no eligible studies for this question.

• Beta‐blockers in patients without heart failure after myocardial infarction 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The review found no eligible studies for this question.

• Beta‐blockers in patients without heart failure after myocardial infarction 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The intervention showed no clear difference in angina pectoris at maximum (low certainty).

• Beta‐blockers in patients without heart failure after myocardial infarction 2021 · Cochrane Headline outcomes only
  RR 1.04 [0.95, 1.13]
  5 studies · 7715 participants
  Low

Intervention not reported

The intervention may leads to lower cardiovascular mortality at maximum (low certainty).

• Beta‐blockers in patients without heart failure after myocardial infarction 2021 · Cochrane Headline outcomes only
  RR 0.73 [0.61, 0.88]
  19 studies · 21763 participants
  Low

Intervention not reported

The intervention probably leads to lower myocardial infarction at maximum (moderate certainty).

• Beta‐blockers in patients without heart failure after myocardial infarction 2021 · Cochrane Headline outcomes only
  RR 0.76 [0.67, 0.86]
  19 studies · 19606 participants
  Moderate

Mineralocorticoid receptor antagonists (MRAs) vs placebo or no treatment

• Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 511 participants
  Low

Angiotensin‐converting enzyme inhibitors vs placebo or no treatment

Angiotensin‐converting enzyme inhibitors (ACEIs) showed no clear difference in cardiovascular mortality (RR) compared with placebo or no treatment (moderate certainty).

• Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved… 2021 · Cochrane Headline outcomes only
  RR 0.93 [0.61, 1.42]
  2 studies · 945 participants
  Moderate

Angiotensin‐converting enzyme inhibitors vs placebo or no treatment

Angiotensin‐converting enzyme inhibitors (ACEIs) showed no clear difference in heart failure hospitalisation (RR) compared with placebo or no treatment (moderate certainty).

• Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved… 2021 · Cochrane Headline outcomes only
  RR 0.86 [0.64, 1.15]
  3 studies · 1019 participants
  Moderate

Angiotensin‐converting enzyme inhibitors vs placebo or no treatment

• Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 74 participants
  Very low

Angiotensin‐converting enzyme inhibitors vs placebo or no treatment

Angiotensin‐converting enzyme inhibitors (ACEIs) showed no clear difference in all‐cause mortality (RR) compared with placebo or no treatment (moderate certainty).

• Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved… 2021 · Cochrane Headline outcomes only
  RR 1.04 [0.75, 1.45]
  5 studies · 1187 participants
  Moderate

Angiotensin‐converting enzyme inhibitors vs placebo or no treatment

• Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 154 participants
  Low